Insulet Corporation

Insulet Corporation

About Insulet Corporation

Simplify's Rating
Why Insulet Corporation is rated
B+
Rated A on Competitive Edge
Rated A on Growth Potential
Rated C on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • Insulet raised $444.4M to optimize capital structure and support growth.
  • Omnipod 5's expansion into five European countries boosts international presence.
  • Winning $452M in a trade secrets trial strengthens Insulet's financial position.

What critics are saying

  • Emerging diabetes care companies may challenge Insulet's market share.
  • Technological advancements require continuous R&D investment to stay competitive.
  • Supply chain vulnerabilities in semiconductor components could disrupt production.

What makes Insulet Corporation unique

  • Insulet leads in tubeless insulin pump technology with its Omnipod brand.
  • The Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • Insulet's multinational RADIANT trial showcases innovation in transitioning from daily injections.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$591.8M

Above

Industry Average

Funded Over

7 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Financial Modeling Prep
Mar 28th, 2025
Insulet Corporation's Financial Efficiency in the Medical Device Industry

Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.

Stock Titan
Mar 18th, 2025
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing

Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.

Stock Titan
Mar 18th, 2025
From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod(R) 5 in Adults and Children with Type 1 Diabetes

Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.

Path8 Video
Mar 11th, 2025
Insulet product launch video

This video helped Insulet launch its new iPhone app.

Financial Modeling Prep
Mar 6th, 2025
Ubiquiti Inc. (NYSE:UI) Outshines Peers in Capital Efficiency

Ubiquiti competes with companies like Fair Isaac Corporation, Paylocity Holding Corporation, Monolithic Power Systems, EPAM Systems, and Insulet Corporation.

Recently Posted Jobs

Sign up to get curated job recommendations

Controls & Instrumentation Technician

$30 - $45/hr

Acton, MA, USA

Pricing Analyst

London, UK + 2 more

Associate Territory Manager - Field Based

$75k - $165k/yr

Springfield, MO, USA

See All Jobs

Insulet Corporation is Hiring for 95 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Insulet Corporation's jobs every few hours, so check again soon! Browse all jobs →

Pricing Analyst

London, UK + 2 more

Associate Territory Manager - Field Based

$75k - $165k/yr

Springfield, MO, USA

See All Jobs

Insulet Corporation is Hiring for 95 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Insulet Corporation's jobs every few hours, so check again soon! Browse all jobs →